A systematic review of the treatment studies in Huntington’s disease since 1990
- 26 January 2007
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Pharmacotherapy
- Vol. 8 (2), 141-153
- https://doi.org/10.1517/14656566.8.2.141
Abstract
Huntington's disease (HD) is an autosomal dominant, inherited, neuropsychiatric disease that gives rise to progressive motor, cognitive and behavioural symptoms. Current drug therapy has no effect on the progression of disability, and the need for any pharmacological treatment should be carefully considered. Hyperkinesias and psychiatric symptoms may respond well to pharmacotherapy, but neuropsychological deficits and dementia remain untreatable. Pharmacological intervention in the treatment of the movement disorder of HD is aimed at restoring the balance of neurotransmitters in the basal ganglia. A surprising amount of current drug therapy of HD in clinical practice is based on studies published before 1990. The authors conducted a systematic review of pharmacological therapy in HD using the available papers that were published between 1990 and 2006.Keywords
This publication has 100 references indexed in Scilit:
- To be or not to be toxic: aggregations in Huntington and Alzheimer diseaseTrends in Genetics, 2006
- Fluoxetine-induced Exacerbation of Chorea in Huntington’s Disease?Pharmacopsychiatry, 2003
- Amantadine in Huntington's disease: open-label video-blinded studyNeurological Sciences, 2002
- High-dose olanzapine in Huntington??s diseaseInternational Clinical Psychopharmacology, 2002
- Reversing Neurodegeneration:A Promise UnfoldsCell, 2000
- Late onset levodopa responsive Huntington's disease with minimal chorea masquerading as Parkinson plus syndromeJournal of Neurology, Neurosurgery & Psychiatry, 2000
- Levodopa responsive parkinsonism in an adult with Huntington's diseaseJournal of Neurology, Neurosurgery & Psychiatry, 1998
- Functional decline in Huntington's diseaseMovement Disorders, 1995
- Leuprolide acetate for exhibitionism in huntington's diseaseMovement Disorders, 1994
- Neuroleptic Malignant Syndrome Related to Tetrabenazine Introduction and Haloperidol Discontinuation in Huntingtonʼs DiseaseClinical Neuropharmacology, 1992